

Medical Report Translation

Name	Laila Mahmoud Abdulqader Aldaqal
Medical Record Number	5334384
Date	03 July 2025
Authenticated By	حسن الخضري

Patient: ALDAQAL, LAILA MAHMOUD ABDULQADER MRN: 5334384 FIN: 36570822

Age: 61 years Sex: Female DOB: 17/11/1963

Associated Diagnoses: None

Author: ALKATTAN, FAISAL WAEL

-

Laila is a 61-year-old female, known case of: - Metastatic breast cancer (bone, leptomeningeal carcinomatosis, pleural?) IDC/ILC HR+ve - S/P Right mastectomy + axillary dissection on May 2021. - Underwent right breast reconstruction with extended LD flap + left breast reduction/mastopexy (Sep 1, 2022)

- Completed adjuvant RT to chest wall & supraclavicular fossa.
- Endocrine Therapy: Letrozole continued post-treatment until 2024.
- Relapsed in April 2025 with triple-negative metastatic recurrence Hx of spinal cord compression (ESCC Grade 3) post XRT to T spine in 15th of april 2025
- New Seizure due to Mets Hydrocephalus S/P VP Shunt on 5/06/2025.
- RTx to brain

٠٩٦٦١١١٤٤١٤٨٣٩. فاكس: ٢٠٩٧٦٦١١١٤٦٤٧٢٧٢ المملكة العربية السعودية. هاتف: ١١٢١١ الرياض ٣٣٥٤ صص.ب :

P.O. Box: 3354 Riyadh 11211, Kingdom of Saudi Arabia, Tel: +96611 4414839 Fax: +96611 4414839







- She developed UGIB on 9/6/2025; endoscopy on 11/6/2025 was free

Code status: DNAR (17/06/2025)

Medical evaluation (17/06/2025)

Transferred to palliative care (23/06/2025)

Reason of Current Admission:

Worsening headache, nausea, and dizziness - S/P VP shunt

Seen by Radiation Oncology and she underwent palliative XRT single-FX 8 Gy to left hip and right shoulder/upper h umerus on 02/07/2025

She is currently on:

- Enoxaparin 60mg qAM and 80mg qPM as per thrombosis team
- Morphine 4mg SC q4hr
- Pregabalin 75mg qAM and 100mg qPM
- Morphine 1.5mg SC q1hr PRN > BTA 0
- Acetaminophen 1g IV q8hr PRN > BTA 0
- Metoclopramide 10mg IV q8hr PRN > BTA 0
- Amitriptyline 25mg qBedtime PRN > BTA 0
- On Laxatives PRN
- Completed her course of Meropenem for UTI

No sign of opioid toxicity, side effect, or dependence

Oral intake: Tolerating

٠٠٩٦٦١١٤٤١٤٨٣٩. فاكس: ٠٠٩٦٦١١٤٦٤٧٢٧٢ المملكة العربية السعودية. هاتف: ١١٢١١ الرياض ٣٣٥٤ صص.ب :

P.O. Box: 3354 Riyadh 11211, Kingdom of Saudi Arabia, Tel: +96611 4414839 Fax: +96611 4414839





Urination: On FC	
------------------	--

Mood: Stable

BM: Passing

Sleep: Maintained

Psychosocial and Spiritual: Stable

PPS: 40-50%

- # From previous primary team:
- To continue meropenem for 14 days starting from 16 June 2025 because of Urinary Tract Infection Extended-Spectrum beta- Lactamase
- We will start the patient's of on enoxaparin for Deep Venous Thrombosis as per thrombosis team (thrombosis team : escalate Enoxaparin to 40 mg bid 22/06/2025)
- # Regarding her current VTE/DVT she is on enoxaparin 40 mg BID. (Thrombosis team 25/06 : to esclatae to theraputic dose 60 mg Qam and 80 mg Qpm.

Labs:

e-GFR > 60

Hb: 92

Plan:

- *Seen and discussed with Dr. Alkhudairi, PCM consultant
- For transfer to long-term care facility (DC planner involved)
- Continue same medical management as detailed above

٠٠٩٦٦١١٤٤١٤٨٣٩. فاكس: ٠٠٩٦٦١١٤٦٤٧٢٧٢ المملكة العربية السعودية. هاتف: ١١٢١١ الرياض ٣٣٥٤ صص.ب :

P.O. Box: 3354 Riyadh 11211, Kingdom of Saudi Arabia. Tel: +96611 4414839 Fax: +96611 4414839

www.kfshrc.edu.sa





- Skin and bowel care as needed
- Benefits and burdens of aforementioned medications discussed and explained
- Remain providing psychosocial and spiritual support to the patient and family

This medical evaluation was done to facilitate transfer to long-term care facility

تم إصدار هذا التقرير من قبل مستشفى الملك فيصل التخصصى ومركز الأبحاث.

This Report has been issued by King Faisal Specialist Hospital & Research Centre.

Kingdom of Saudi Arabia

٠٠٩٦٦١١٤٤١٤٨٣٩. فاكس: ٠٠٩٦٦١١٤٦٤٧٢٧٢ المملكة العربية السعودية. هاتف: ١١٢١١ الرياض ٣٣٥٤ صص.ب :

P.O. Box: 3354 Riyadh 11211, Kingdom of Saudi Arabia. Tel: +96611 4414839 Fax: +96611 4414839



